SHLT VS CDXS Stock Comparison
Performance
SHLT10/100
10/100
SHLT returned -38.07% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
CDXS10/100
10/100
CDXS returned -70.66% in the last 12 months. Based on SPY's performance of -12.14%, its performance is below average giving it a score of 10 of 100.
Profit
SHLT56/100
56/100
Out of the last 20 quarters, SHLT has had 8 profitable quarters and has increased their profits year over year on 6 of them.
CDXS16/100
16/100
Out of the last 20 quarters, CDXS has had 2 profitable quarters and has increased their profits year over year on 2 of them.
Volatility
SHLT50/100
50/100
SHLT has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
CDXS41/100
41/100
CDXS has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
Analyst Price Targets
SHLT
"Analyst Price Targets" not found for SHLT
CDXS75/100
75/100
4 analysts offer 12-month price targets for CDXS. Together, they have an average target of 0, the most optimistic target put CDXS at 0 within 12-months and the most pessimistic has CDXS at 0.
Sentiment
SHLT
"Sentiment" not found for SHLT
CDXS72/100
72/100
CDXS had a bullish sentiment score of 71.51% across Twitter and StockTwits over the last 12 months. It had an average of 3.21 posts, 0.68 comments, and 1.89 likes per day.
Technicals
SHLT
"Technicals" not found for SHLT
CDXS64/100
64/100
CDXS receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
SHLT
"Earnings" not found for SHLT
CDXS40/100
40/100
CDXS has missed earnings 4 times in the last 20 quarters.
All score calculations are broken down here to help you make more informed investing decisions
SHL Telemedicine Ltd American Depositary Shares Summary
Nasdaq / SHLT
Healthcare
Medical - Healthcare Information Services
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.
Codexis, Inc. Summary
Nasdaq / CDXS
Healthcare
Biotechnology
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare SHLT to other companies in the same or a similar industry.